Product Description
a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. (Sourced from: https://drugs.ncats.io/drug/PR82C5R514)
Mechanisms of Action: Sterol Synthesis Inhibition,Fungal Growth Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ferrer Internacional
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Candidiasis, Vulvovaginal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
P-090756-01 | P2 |
Completed |
Candidiasis, Vulvovaginal |
2011-03-01 |
|
2009-016655-21 | P2 |
Completed |
Candidiasis, Vulvovaginal |
2010-11-15 |